Clinical trial
Esomeprazole in PPI Failures - IMPROVE
NCT00272701 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00272701 |
|---|---|
| Title | Esomeprazole in PPI Failures - IMPROVE |
| Official title | A Randomised, Open, Phase IV, Parallel Group Multicentre Study to Evaluate a Change of Management in Gastroesophageal Reflux Disease (GERD) Patients by Treatment With Esomeprazole 40 mg or Any Other Proton Pump Inhibitor (PPI), After Initial Treatment Failure, in Ordinary Clinical Practice During 4… |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Gastroesophageal Reflux Disease |
| Intervention type | Drug |
| Interventions | Esomeprazole, Other PPI marketed in Sweden |
| Enrollment | 450 |
| Start date | Dec 1, 2005 |
| Completion | Feb 1, 2007 |
| First posted | Jan 9, 2006 |
| Last update posted | Mar 6, 2009 |
| Countries | Sweden |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: